Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.62 |
| ▸ | AHR | P35869 | 1/20 | 0.51 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.47 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10714519 | 0.89 | PDE3B (0.57) | MAOBAHREIF2AK2GRIA1CACNG8 | |
| SCHEMBL10375833 | 0.88 | MAOB (0.65) | MAOBAHREIF2AK2MAOAKCNH2 | |
| SCHEMBL12431389 | 0.87 | EIF2AK2 (0.68) | MAOBAHREIF2AK2MAOAMAPT | |
| SCHEMBL2205572 | 0.86 | MAOA (0.66) | MAOBMAOAPDE3BPDE3A | |
| SCHEMBL14815914 | 0.83 | MAOB (0.52) | MAOBMAPTHSD17B10PDE3BPDE3A | |
| SCHEMBL14333290 | 0.83 | MAOB (0.71) | MAOBAHREIF2AK2MAOAKCNH2 | |
| SCHEMBL20214 | 0.81 | PDE3B (0.66) | MAOBAHREIF2AK2MAOAGRIA1 | |
| SCHEMBL31040124 | 0.81 | PDE3B (0.66) | MAOBAHREIF2AK2MAOAGRIA1 | |
| SCHEMBL7404515 | 0.81 | MAOB (0.65) | MAOBAHREIF2AK2MAOAGRIA1 | |
| SCHEMBL3259635 | 0.80 | MAOB (0.58) | MAOBAHREIF2AK2MAOAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140205537-A1 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2012178015-A2 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012178015-A2 | LRRK2 INHIBITORS | ZENOBIA THERAPEUTICS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| EP-2123649-B1 | 3-PYRROLO-CYCLOHEXYLENE-2-DIHYDRO-INDOLINONE DERIVATIVES AND USES THEREOF | JIANGSU SIMCERE PHARMACEUTICAL R & D CO LTD (CN) | 2012-02-29 | — | — | EP | disclosed |
| US-8084621-B2 | 3-Pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives and uses thereof | Jiangsu Simcere Pharmaceutical R&D Co. Ltd. (CN) | 2011-12-27 | — | — | US | disclosed |
| US-20100160318-A1 | 3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof | JIANGSU SIMCERE PHARMACEUTICAL R&D CO., LTD. (CN) | 2010-06-24 | — | — | US | disclosed |
| EP-2123649-A1 | 3-PYRROLO-CYCLOHEXYLENE-2-DIHYDRO-INDOLINONE DERIVATIVES AND USES THEREOF | Jiangsu Simcere Pharmaceutical R&D Co., Ltd. (CN) | 2009-11-25 | — | — | EP | disclosed |
| EP-2020408-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | Sugen, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-4658037-A | RHEUMATIC DISEASES | PFIZER INC. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4652658-A | Process for making 2-oxindole-1-carboxamides and intermediates therefor | PFIZER INC. (US) | 1987-03-24 | — | — | US | disclosed |
| US-4622336-A | ANALGESICS | SANDOZ LTD. (CH) | 1986-11-11 | — | — | US | disclosed |
| EP-0175551-A1 | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds | PFIZER INC. (US) | 1986-03-26 | — | — | EP | disclosed |
| US-4569942-A | N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents | PFIZER INC. (US) | 1986-02-11 | — | — | US | disclosed |
| EP-0164860-A1 | N,3-disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents | PFIZER INC. (US) | 1985-12-18 | — | — | EP | disclosed |
| US-4556672-A | 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0156603-A2 | 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0155828-A2 | Process for making 2-oxindole-1-carboxamides and intermediates therefor | PFIZER INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0153818-A2 | 1,3-Disubstituted 2-oxindoles as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160318-A1 | 3-Pyrrolo[b]Cyclohexylene-2-Dihydroindolinone Derivatives and Uses Thereof | PTK2B, DMPK, STK25 | MAOB 1059/4885AHR 1528/4885EIF2AK2 770/4885 |
| US-20140205537-A1 | LRRK2 INHIBITORS | LRRK2, PARK7, MAP2 | MAOB 1759/4885AHR 4284/4885EIF2AK2 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.